RetinaLyze International

RetinaLyze International Safe, fast and efficient retinal investigations with RetinaLyze AI and Telemedicine. Retinalyze is based on the vision to prevent loss of eyesight.

Worldwide diabetes is an increasing problem and +300 million registered diabetics (type 1 or 2) are expected in 2020. Furthermore by 2020 +250 million unregistered diabetics are expected. One of the most feared consequences of diabetes is retinal diabetic pathology since this can lead to blindness. Early diagnosis is crucial – and possible with Retinalyze. A good diabetic plan and a non-complicated laser treatment can prevent loss of sight and blindness. Our mission is to make it easier for people all over the world to have their eyes tested and prevent the tragic consequences caused by late treatment of retinal lesions. Retinalyze System A/S is a registered company in Denmark.

20/11/2025

Coming soon to RetinaLyze: 3D optic nerve insights from a simple 2D photo! ✨

We’re excited to introduce a new RetinaLyze feature that visualizes a 3D view of the optic nerve head directly from a standard fundus image.

No OCT required.

Built on research published in BMJ Open Ophthalmology (2025) and powered by 1.1M+ optic nerve images, this update brings perfusion-based structural analysis into everyday screening.

What this means for eye care professionals:
- Optometrists: Get meaningful 3D disc & cup visualization where OCT isn’t available. Track change over time and support stronger referrals.

- Ophthalmologists: Add a fast, quantitative, perfusion-driven perspective that complements OCT. Especially in satellite or mobile clinics.

The science is clear: local hemoglobin distribution strongly correlates with OCT thickness (R = 0.953), and reconstructed rim/cup volumes align closely with OCT measurements.

This is another step toward democratizing advanced glaucoma analysis and improving collaboration across the eye-care pathway.

The next generation of clinicians won’t succeed by memorizing more facts, but by learning to think with intelligent syst...
18/11/2025

The next generation of clinicians won’t succeed by memorizing more facts, but by learning to think with intelligent systems at their side.

By reinforcing skills like communication, empathy and observation.

That’s why the perspective from New England College of Optometry resonates so strongly with us at RetinaLyze.

If students aren’t learning how to collaborate with AI, question it, audit it and use it to sharpen their clinical judgment, they’re already behind.

The clinician of tomorrow must be able to:
- supervise agentic AI, not be supervised by it
- combine empathy with data-driven clarity
- deliver consistent, high-quality care even in high-volume settings
- make faster, safer decisions with support from intelligent tools

In other words:
AI-ready optometrists = better patient outcomes.

We’re proud to stand alongside educators and innovators from New England College of Optometry (NECO) Center for Eye Caret to partners like Heidelberg Engineering, Topcon Healthcare, TOMEY GmbH, Medibrix and others who share this mission.

At RetinaLyze, we believe in clinicians who stay human, stay sharp and stay supported by reliable AI. That’s the future we’re building for.

For me, Ganesh, this day has always been more than a campaign. It’s personal.My dad lived with diabetes for many years. ...
14/11/2025

For me, Ganesh, this day has always been more than a campaign. It’s personal.

My dad lived with diabetes for many years. I saw up close how much strength it takes.

The daily routines, the discipline, the worries, and, most of all, the hope of keeping things under control.

What stayed with me most was the fear of losing sight. Vision is such a fundamental part of independence and dignity and for so many living with diabetes, it’s at risk far too soon.

That’s one of the reasons we built RetinaLyze: to make sure that no one loses their vision to diabetic eye disease simply because it wasn’t caught in time.

To make eye screenings more accessible.

With our AI-powered retinal screening, eye care professionals across the world can detect early signs of diabetic retinopathy.

I hope it gives patients and families the chance to act before it’s too late.

Today, on , I think of my dad and of every person who faces diabetes with courage every single day.

As part of the expanding Heidelberg Engineering AppWay ecosystem, we’re thrilled to showcase how RetinaLyze® helps eye c...
11/11/2025

As part of the expanding Heidelberg Engineering AppWay ecosystem, we’re thrilled to showcase how RetinaLyze® helps eye care professionals detect signs of pathology such as diabetic retinopathy, AMD, and glaucoma.

Join Teddy Birch Petersen (CEO & Owner) and Ganesh Ram (CCO & Founder) from RetinaLyze System A/S as they present:

Webinar: "RetinaLyze – AI-Powered Eye Screening"
Date: Wednesday, 26 November 2025
Time: 1:00–2:00 PM CET

Learn how RetinaLyze, our CE-certified, AI-powered eye screening software, provides instant, reproducible analyses of fundus images helping clinics save time, standardize care, and prevent avoidable vision loss.

We look forward to connecting with the community of optometrists, ophthalmologists, and eye care innovators joining this session!

👉 Register via Heidelberg Engineering’s official channels, or directly via this link: https://go.heidelbergengineering.com/l/187512/2025-10-27/4237g9r

04/11/2025

Every day, optometrists and ophthalmologists work on the frontlines of vision health.

Detecting diseases that often show no early symptoms but can lead to lifelong blindness if missed.

At RetinaLyze, we believe technology should empower these professionals. Not replace them.

Our mission is simple: to make early detection of retinal diseases accessible, fast, and reliable.

Using AI-based image analysis, RetinaLyze helps eye care professionals:
Detect signs of eye diseases such as diabetic retinopathy, AMD, and glaucoma in seconds.

Integrate screening directly into their daily workflow. No complex setup or hardware changes needed.

Collaborate with specialists remotely, ensuring every patient can access the right care at the right time.

For over a decade, RetinaLyze has supported optometrists, ophthalmologists, and healthcare chains worldwide. We've screened millions of patients, preventing avoidable vision loss.

But what truly sets us apart is not just the AI.

It’s the combination of clinical validation, telemedicine workflow, and human collaboration that ensures every result leads to meaningful action.

Because in the end, technology doesn’t save sight. People who care about eyecare do.

Proud moment for us all at RetinaLyze System A/S! ✨A new study supporting the use of RetinaLyze Glaucoma is now publishe...
29/10/2025

Proud moment for us all at RetinaLyze System A/S! ✨

A new study supporting the use of RetinaLyze Glaucoma is now published in one of the most the prestigious publications in the world: Scientific Reports.

𝐖𝐡𝐚𝐭 𝐰𝐚𝐬 𝐬𝐭𝐮𝐝𝐢𝐞𝐝
Design: Cross-sectional analysis of 89 eyes from 57 glaucoma patients.
Imaging & tests: Standard color fundus photos analyzed with automated colorimetry (RetinaLyze Glaucoma known as Laguna ONhE in research), plus OCT/OCTA and visual fields (Octopus 900).

What RetinaLyze Glaucoma measures: Optic nerve head hemoglobin (ONH Hb) distribution across 24 sectors, yielding indices such as GDF and GIP that relate to cup/rim morphology and cup-to-disc ratio.

𝐊𝐞𝐲 𝐭𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬
ONH Hb tracks damage: RetinaLyze Glaucoma indices correlated significantly with RNFL and GCL thickness and with visual-field metrics. This supports ONH Hb as a practical, non-invasive marker of structural/functional loss in glaucoma.

Speed + cost matter: For large-scale screening, methods that are fast and cost-effective enable broader coverage; RetinaLyze Glaucoma uses a standard fundus camera and delivers quantitative, repeatable outputs.

Monitoring over time: The software quantifies cup/rim and sectoral Hb patterns, helping flag subtle changes near the edge of normality and compare images across follow-up.

𝐖𝐡𝐲 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬
Vascular factors play a major role in glaucoma. Evaluating ONH Hb offers an accessible window into perfusion-linked structural damage and complements OCT/OCTA where cost, availability, or anatomy are limiting.

Link to the paper in the comments!

Thanks and congratulations to the author team: Gustavo Caiado, Gustavo Samico, Gilvan V. da Silva Filho, sergio teixeira, Tiago Prata, Carolina Pelegrini Barbosa Gracitelli, Augusto Paranhos and to collaborators and technology partners who make this work possible.

AI in eye care only works when trust, workflow and patient connection come first.This recent piece by Dr. Scot Morris, O...
27/10/2025

AI in eye care only works when trust, workflow and patient connection come first.

This recent piece by Dr. Scot Morris, OD lays out the real hurdles: clinician trust (the “black box” problem), implementation cost and complexity, and patient concerns about losing the human touch.

These are exactly the challenges we’ve designed RetinaLyze to address.

How we approach it at RetinaLyze:
- Clinician-first transparency with clear results and visual cues so decisions are explainable.
- Fits your workflow with simple deployment, training and support that help teams adopt AI without disrupting patient flow.
- Augments, not replaces eye care professionals. AI flags risk, optometrists and ophthalmologists make the call. The patient relationship stays at the center.

If you’re an ECP, clinic leader or distributor exploring AI-enabled screening and telemedicine pathways, let’s talk about pragmatic steps to build trust, efficiency and access.

👉 Read the conversation starter from AI in Eye Care and Dr. Scot Morris, OD: https://aiineyecare.com/what-hurdles-must-ai-clear/

Congratulations to the Danish-LATAM Health Alliance - the team at The Trade Council of Denmark in Latin America, the mem...
22/10/2025

Congratulations to the Danish-LATAM Health Alliance - the team at The Trade Council of Denmark in Latin America, the members and participants in the first events! 👏 💯

At yesterdays event on PPP (Private Public Partnerships) RetinaLyze had the honour to share experiences on how to create positive outcomes for patients and parties involved. We presented for healthcare stakeholders from Brazil, Mexico, Chile, Columbia and Costa Rica alongside brilliant speakers with impressive presentations. It was a true pleasure to listen and learn from you Maria Kristiansen, Lars Hulbaek, Jens-Christian Holm, Julia Abrams, Simon Madsen, Patricia Byington and others joining! Thanks! 🙌 🥳

Well done and kudos to Tina Gottlieb, Laura Caroline Leme Bonani, Danilo Guimarães, Carlos Manuel Castillo Vázquez, Magnus Teis Rasmussen Wøhler, Benjamin Thokwa Brown, Anne Mette Vega Brondbjerg, Rebeca de Carvalho Ferreira and acosta! 🙌
You succeed with bringing the purpose to live: Sharing knowledge and best practices across the countries, exploring innovative healthcare and digital solutions, support building partnerships that target multi-stakeholder solutions in prevention, care, and rehabilitation and paving the way for sustainable solutions for healthier and more empowered ageing populations. 🙏

Good clinical records is your best insurance!We’ve turned key takeaways on good clinical record keeping into a quick, pr...
22/10/2025

Good clinical records is your best insurance!

We’ve turned key takeaways on good clinical record keeping into a quick, practical guide for optometrists.

Based on advice from Henrik Holton, Expert at Styrelsen for Patientklager and optometrist at Synscentralen i Vordingborg (Denmark).

This general guidance follows Danish standards. Always check local regulations in your country/region.

Read the full guide 👉 www.retinalyze.com/post/good-clinical-record-keeping-for-optometrists-a-practical-guide

Wow! I (Teddy) just dropped by our customer Cornelius K in Denmark.What a pleasure to step into such a beautifully cura...
20/10/2025

Wow! I (Teddy) just dropped by our customer Cornelius K in Denmark.

What a pleasure to step into such a beautifully curated store. The space reflects owners Annette Thue Holmstrøm and Daniel Back and their team’s commitment to going the extra mile to create outstanding experiences for every customer.

Many thanks to Daniel for the positive feedback on your use of RetinaLyze AI.

It was lovely to say a quick hello! Customers in the store rightly come first. Thank you!

NAION is now listed as a very rare side effect with semaglutide (Ozempic, Wegovy, Rybelsus)!The European Medicines Agenc...
15/10/2025

NAION is now listed as a very rare side effect with semaglutide (Ozempic, Wegovy, Rybelsus)!

The European Medicines Agency has confirmed that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide-based medicines and has updated EU product information accordingly (“very rare” =

Adresse

Mileparken 10C
Skovlunde
2740

Åbningstider

Mandag 09:00 - 17:30
Tirsdag 09:00 - 17:30
Onsdag 09:00 - 17:30
Torsdag 09:00 - 17:30
Fredag 09:00 - 17:30

Internet side

Underretninger

Vær den første til at vide, og lad os sende dig en email, når RetinaLyze International sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Kontakt Praksis

Send en besked til RetinaLyze International:

Genveje

Del

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Prevention of blindness through AI

RetinaLyze prevents loss of eyesight by making eye screening accessible. 80% of all blindness is preventable. Early screening and diagnosis is crucial and possible with Retinalyze'​ automated retinal screening tools and telemedicine solutions. Our mission is to make it easier for people all over the world to have their eyes tested and prevent the tragic consequences caused by late treatment of retinal lesions.

RetinaLyze® is a screening software, which helps eye care professionals perform screenings for eye diseases in a safe and efficient manner. The automated algorithm (AI) module detects eye diseases by analyzing fundus images. It can be used as a clinical decision support system (CDSS) or as a screening tool in conjunction with the telemedicine module. Retinalyze System A/S is a registered company in Denmark. Check us out at https://RetinaLyze.com.